Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

miR-639 promotes the proliferation and invasion of breast cancer cell in vitro

Authors: Lin Li, Xin-guang Qiu, Peng-wei Lv, Fang Wang

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Breast cancer is characterised by an elevated capacity for tumour invasion and lymph node metastasis, but the cause remains to be determined. Recent studies suggest that microRNAs can regulate the evolution of malignant behaviours by regulating multiple target genes. In this study, we have first confirmed that miR-639 is up-regulated in metastatic breast cancer tissues and cell line with highly invasive capacity. Furthermore, we provided evidence to demonstrate that up-regulation of miR-639 contributes breast cancer invasion and metastasis. These data reveal a key role of miR-639 in breast cancer metastasis and support biological and clinical links between miR-639 and breast cancer.
Appendix
Available only for authorised users
Literature
1.
Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK: Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013, 19 (23): 6389-6397. 10.1158/1078-0432.CCR-13-0838.CrossRefPubMed
2.
3.
Schickel R, Boyerinas B, Park SM, Peter ME: MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008, 27 (45): 5959-5974. 10.1038/onc.2008.274.CrossRefPubMed
4.
Zhang J, Guo H, Qian G, Ge S, Ji H, Hu X, Chen W: MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network. Mol Cancer. 2010, 9: 211-CrossRefPubMedCentralPubMed
5.
6.
Kent OA, Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006, 25 (46): 6188-6196. 10.1038/sj.onc.1209913.CrossRefPubMed
7.
Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6 (11): 857-866. 10.1038/nrc1997.CrossRefPubMed
8.
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L, Liang A, Tao W, Cao X: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011, 19 (2): 232-243. 10.1016/j.ccr.2011.01.001.CrossRefPubMed
9.
Ragusa M, Caltabiano R, Russo A, Puzzo L, Avitabile T, Longo A, Toro MD, Di Pietro C, Purrello M, Reibaldi M: MicroRNAs in vitreus humor from patients with ocular diseases. Mol Vis. 2013, 19: 430-440.PubMedCentralPubMed
10.
Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Muller SC, Ellinger J: Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?. World J Urol. 2012, 32 (2): 353-358.CrossRefPubMed
11.
Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007, 39 (5): 673-677. 10.1038/ng2003.CrossRefPubMed
12.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-838. 10.1038/nature03702.CrossRefPubMed
13.
Ozen M, Creighton CJ, Ozdemir M, Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008, 27 (12): 1788-1793. 10.1038/sj.onc.1210809.CrossRefPubMed
14.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006, 103 (7): 2257-2261. 10.1073/pnas.0510565103.CrossRefPubMedCentralPubMed
15.
Sun Q, Zhang J, Cao W, Wang X, Xu Q, Yan M, Wu X, Chen W: Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin. Int J Biochem Cell Biol. 2013, 45 (3): 513-520. 10.1016/j.biocel.2012.12.004.CrossRefPubMed
16.
O’Regan EM, Toner ME, Finn SP, Fan CY, Ring M, Hagmar B, Timon C, Smyth P, Cahill S, Flavin R, Sheils OM, O'Leary JJ: p16(INK4A) genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. Hum Pathol. 2008, 39 (3): 452-458. 10.1016/j.humpath.2007.08.004.CrossRefPubMed
17.
18.
Wu S, Huang S, Ding J, Zhao Y, Liang L, Liu T, Zhan R, He X: Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′ untranslated region. Oncogene. 2010, 29 (15): 2302-2308. 10.1038/onc.2010.34.CrossRefPubMed
Metadata
Title
miR-639 promotes the proliferation and invasion of breast cancer cell in vitro
Authors
Lin Li
Xin-guang Qiu
Peng-wei Lv
Fang Wang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-14-39

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue

Primary research

Association between genetic polymorphisms in AURKA (rs2273535 and rs1047972) and breast cancer risk: a meta-analysis involving 37,221 subjects

Primary research

Electromagnetic field investigation on different cancer cell lines

Primary research

K-D:rib dampens Hs 578T cancer cell chemoinvasion and proliferation

Primary research

Decreased expression of the Nkx2.8 gene correlates with tumor progression and a poor prognosis in HCC cancer

Review

New strategy to control cell migration and metastasis regulated by CCN2/CTGF

Primary research

Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits